Repare Therapeutics Inc

NASDAQ:RPTXUnited States

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Contact Information

Headquarters

7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1

Phone

---

Fax

---

Executives

Independent Chairman of the Board

Thomas Civik

President, Chief Executive Officer, Director

Lloyd Segal

Chief Financial Officer, Executive Vice President

Steve Forte

Executive Vice President, Chief Scientific Officer

Michael Zinda

Executive Vice President, Chief Medical Officer

Maria Koehler